Please use this identifier to cite or link to this item:
|Title:||The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review.||Austin Authors:||Allan, Zexi;Witts, Sasha;Tie, Jeanne;Tebbutt, Niall C ;Clemons, Nicholas J;Liu, David Shi Hao||Affiliation:||Division of Cancer Research, Peter MacCallum Cancer Centre, 305 Grattan Street, Parkville, VIC, 3000, Australia.;Sir Peter MacCallum Department of Oncology, University of Melbourne, Grattan Street, Parkville, VIC, 3000, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Grattan Street, Parkville, VIC, 3000, Australia.;Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Parkville, VIC, 3000, Australia.;The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, 3052, Australia.
Department of Surgery, University of Melbourne, Grattan Street, Parkville, VIC, 3000, Australia.;Department of Medical Oncology, Austin Health, 145 Studley Road, Heidelberg, VIC, 3084, Australia.
Division of Surgery, Anaesthesia and Procedural Medicine
Surgery (University of Melbourne)
|Issue Date:||Nov-2023||Date:||2023||Publication information:||British Journal of Cancer 2023-11; 129(11)||Abstract:||Peritoneal metastases from various abdominal cancer types are common and carry poor prognosis. The presence of peritoneal disease upstages cancer diagnosis and alters disease trajectory and treatment pathway in many cancer types. Therefore, accurate and timely detection of peritoneal disease is crucial. The current practice of diagnostic laparoscopy and peritoneal lavage cytology (PLC) in detecting peritoneal disease has variable sensitivity. The significant proportion of peritoneal recurrence seen during follow-up in patients where initial PLC was negative indicates the ongoing need for a better diagnostic tool for detecting clinically occult peritoneal disease, especially peritoneal micro-metastases. Advancement in liquid biopsy has allowed the development and use of peritoneal tumour DNA (ptDNA) as a cancer-specific biomarker within the peritoneum, and the presence of ptDNA may be a surrogate marker for early peritoneal metastases. A growing body of literature on ptDNA in different cancer types portends promising results. Here, we conduct a systematic review to evaluate the prognostic impact of ptDNA in various cancer types and discuss its potential future clinical applications, with a focus on gastrointestinal and gynaecological malignancies.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/33767||DOI:||10.1038/s41416-023-02424-6||ORCID:||0000-0001-7106-3461
|Journal:||British Journal of Cancer||PubMed URL:||37700064||ISSN:||1532-1827||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 7, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.